Results 11 to 20 of about 692,682 (292)

5-Year simulation of diabetes-related complications in people treated with tirzepatide or semaglutide versus insulin glargine. [PDF]

Diabetes Obes Metab, 2023
Niu S, Alkhuzam KA, Guan D, Jiao T, Shi L, Fonseca V, Laiteerapong N, Ali MK, Schatz DA, Guo J, Shao H.   +10 more
europepmc   +3 more sources

Frequency and Severity of Hypoglycemia Under Conditions of Increased Hypoglycemic Risk with Insulin Efsitora Alfa Versus Insulin Glargine Treatment in Participants with Type 2 Diabetes. [PDF]

Diabetes Ther
Heise T, Andersen G, Pratt EJ, Leohr J, Fukuda T, Wang Q, Kazda C, Bue-Valleskey JM, Bergenstal RM.   +8 more
europepmc   +3 more sources

Cloning and Extracellular Expression of Glargine in Pichia pastoris

Hayati Journal of Biosciences, 2023
Patients with diabetes mellitus increase significantly every year. The increasing number of people with diabetes mellitus results in increased insulin requirements.
Dudi Hardianto, Efrida Martius, Tina Rostinawati, Anna Safarrida, Juwartina Ida Royani, Fahroziah Assyifa, Dihan Laziba   +6 more
doaj   +1 more source

Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.

Journal of the American Medical Association (JAMA), 2022
Importance The effects of tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, as an addition to insulin glargine for treatment of type 2 diabetes have not been described.
D. Dahl, Y. Onishi, P. Norwood, Ruth Huh, R. Bray, Hiren Patel, Angel Rodríguez   +6 more
semanticscholar   +1 more source

Once-Weekly Insulin Icodec vs. Once-Daily Insulin Glargine U100 for type 2 diabetes: a systematic review and meta-analysis of phase 2 randomized controlled trials

Archives of Endocrinology and Metabolism, 2023
Objective: Insulin Icodec is a novel basal insulin analogue designed for once-weekly administration, therefore might propitiate reduction in the frequency of injections and facilitate treatment adherence.
R. Silva, M. Gauza, M. E. S. Guisso, Júlia Opolski Nunes da Silva, Suely Keiko Kohara   +4 more
semanticscholar   +1 more source

Hypoglycaemia frequency and physiological response after double or triple doses of once-weekly insulin icodec vs once-daily insulin glargine U100 in type 2 diabetes: a randomised crossover trial

Diabetologia, 2023
This study compared the frequency of hypoglycaemia, time to hypoglycaemia and recovery from hypoglycaemia after double or triple doses of once-weekly insulin icodec vs once-daily insulin glargine U100.
T. Pieber, Kristine Arfelt, Roman Cailleteau, Marlies Hart, S. Kar, Ines Mursic, E. Svehlikova, Martina Urschitz, H. Haahr   +8 more
semanticscholar   +1 more source

Insulin glargine and cancer risk in patients with diabetes: a meta-analysis. [PDF]

PLoS ONE, 2012
AimThe role of insulin glargine as a risk factor for cancer is controversial in human studies. The aim of this meta-analysis was to evaluate the relationship between insulin glargine and cancer incidence.MethodsAll observational studies and randomized ...
Xulei Tang, Lin Yang, Zhiyu He, Jingfang Liu   +3 more
doaj   +1 more source

Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin.

New England Journal of Medicine, 2023
BACKGROUND Insulin icodec is an investigational once-weekly basal insulin analogue for diabetes management. METHODS We conducted a 78-week randomized, open-label, treat-to-target phase 3a trial (including a 52-week main phase and a 26-week extension ...
J. Rosenstock, S. Bain, A. Gowda, E. Jódar, Bo Liang, I. Lingvay, Tomoyuki Nishida, R. Trevisan, Ofri Mosenzon   +8 more
semanticscholar   +1 more source

Comparison between basal insulin glargine and NPH insulin in patients with diabetes type 1 on conventional intensive insulin therapy [PDF]

Vojnosanitetski Pregled, 2007
Background/Aim. Insulin glargine is a long-acting insulin analog that mimics normal basal insulin secretion without pronounced peaks. The aim of this study was to compare insulin glargine with isophane insulin (NPH insulin) for basal insulin supply in ...
Pešić Milica, Živić Saša, Radenković Saša, Velojić Milena, Dimić Dragan, Antić Slobodan   +5 more
doaj   +1 more source

A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100

Diabetes Care, 2021
OBJECTIVE Insulin icodec is a novel once-weekly basal insulin analog. This trial investigated the efficacy and safety of icodec using different once-weekly titration algorithms.
I. Lingvay, J. Buse, E. Franek, M. V. Hansen, M. Koefoed, C. Mathieu, J. Pettus, Karolina Stachlewska, J. Rosenstock   +8 more
semanticscholar   +1 more source